一品红(300723.SZ)：重酒石酸利斯的明口服溶液获注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for its oral solution of Ropinirole Tartrate, which is indicated for the treatment of mild to moderate Alzheimer's disease symptoms [1] Company Summary - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Ropinirole Tartrate oral solution [1] - The approved indication for the drug is specifically for treating symptoms associated with mild to moderate Alzheimer's type dementia [1]